Loading Page
Dr. Amma Owusu-Ansah, MD is a physician provider in Cleveland, OH specializing in physician, pediatric hematology and general pediatrics. She graduated from University Of Ghana in 1997 and has 29 years of experience. Dr. Amma Owusu-Ansah, MD is affiliated with University Hospitals and North Ridgeville HC Ste 2200.
Dr. Amma Owusu-Ansah, MD graduated from University Of Ghana in 1997. She completed residency at John H Stroger, Jr Hospital Of Cook County. She is certified by the Pediatric Hematology-Oncology - American Board of Pediatrics Pediatrics - American Board of Pediatrics and has a state license in Connecticut.
Medical School: University Of Ghana (1997)
Residency: John H Stroger, Jr Hospital Of Cook County (2004)
Board Certification: Pediatric Hematology-Oncology - American Board of Pediatrics Pediatrics - American Board of Pediatrics
Licensed In: Connecticut
Dr. Amma Owusu-Ansah, MD does not have any reviews yet, be the first to leave a review of Dr. Amma Owusu-Ansah, MD here: Leave a Review
These charts describe general payments received by Dr. Amma Owusu-Ansah, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
|
$214
OXBRYTA $189 |
HYMPAVZI $25 |
|||||
|
$155
FERRIPROX $155 |
||||||
|
$87
HEMGENIX $56 |
Idelvion $16 |
Afstyla $15 |
||||
|
$67
ESPEROCT $31 |
Alhemo $19 |
$17 |
||||
|
$66
ULTOMIRIS $66 |
||||||
|
$319
Vitrakvi $46 |
OXBRYTA $46 |
ALPROLIX $43 |
HEMLIBRA $34 |
VONVENDI $29 |
Other $122 |
| $908 |
Dr. Amma Owusu-Ansah, MD has received 41 research payments totaling $172,640.
Amma Owusu-Ansah, MD, is an Associate Professor of Pediatrics focused on improving access to state-of-the-art medical care, including disease modifying therapies for children with sickle cell disease (SCD) and blood disorders. Her areas of expertise are SCD, benign hematology and global hematology. Dr. Owusu-Ansah is the physician lead for the Pediatric Sickle Cell Anemia Center at UH Rainbow Babies & Children’s Hospital. Her interests include improving health outcomes for transition-aged young patients using an evidence-based transition program and teaching curriculum, increasing access of pediatric SCD patients to transformative therapies and building hematology capacity to improve outcomes in limited resource settings.
